Neoantigens — or tumor mutated specific antigens (TMSA) — are a major tumor rejection antigen, which allows tumors to activate the immune system and induce an efficient anti-tumor response.
As personalized medicine for cancer therapeutics ramps up and becomes more feasible and affordable, individual patient neoantigen development is increasingly important.
Identification of these neoantigens has been greatly improved with recent advancements in deep sequencing and bioinformatics technologies. Gene synthesis then allows for these predicted neoantigens to be synthesized and tested for T cell reactivity, differentiating true immunogenic neoepitopes from putative ones.
Accelerating personalized neoantigen development
Since patients’ mutated antigens are largely unique to the individual, speed is one of the most important variables for identifying and verifying true neoantigens for induction of the T cell-mediated immune response. The BioXp™ 3200 system's high-throughput gene synthesis and flexible cloning into a variety of vectors allow for quick screening and development of the best personalized cancer treatment. Additionally, for the initial screening process, avoid E. coli with RapidAMP™ cloning and amplification, negating endotoxin contamination concerns and unwanted immunogenicity.